CUPR FDA clearance for MEDIFLY maggots drives

 

Momentum from June 15 FDA clearance for MEDIFLY maggots drives 79% CUPR premarket surge

• Cuprina received U.S. FDA 510(k) clearance on June 15 for MEDIFLY, first-ever for Lucilia cuprina maggot debridement product for chronic wounds (GlobeNewswire).
• Prior surges exceeded 150% and 100%+ on FDA news plus June 12 Nasdaq compliance regain; stock remains highly volatile post-reverse split.
• Closed June 22 at ~$3.93 (down 10%); today's premarket pop to near $7 area reflects low-float momentum trading.
• Recent X/trader chatter highlights price targets ($5) and support levels with no new announcements cited.
• Maggot debridement therapy (MDT) is established for wound care; clearance expands U.S. commercialization potential for biomedical firm.
• No fresh company press release or fundamental update identified for June 23-24 specifically.

https://finviz.com/stock?t=CUPR&p=d